O. Hamid

O. Hamid, S. Klempner, P. Mehta, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer

R. Carvajal, O. Hamid, Brianna Hoffner, 2017, Cancer Immunology, Immunotherapy.

Quantitative Metastatic Lymph Node Burden and Survival in Merkel Cell Carcinoma.

M. Luu, A. Ho, Z. Zumsteg, 2020, Journal of the American Academy of Dermatology.

The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018

P. Ascierto, A. Testori, H. Tawbi, 2019, Journal of Translational Medicine.

Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies

J. Marshall, R. Kurzrock, P. Munster, 2014, Cancer Chemotherapy and Pharmacology.

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

J. Wolchok, H. Zarour, N. Ibrahim, 2019 .

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

M. Atkins, F. Hodi, H. Tawbi, 2018, The New England journal of medicine.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors.

H. Kohrt, J. Tabernero, Daniel S Chen, 2013 .

Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.

D. Schadendorf, J. Wolchok, M. Maio, 2010, Cancer immunity.

SARS-CoV-2 vaccine uptake, perspectives, and adverse reactions following vaccination in patients with cancer undergoing treatment

A. Mita, O. Hamid, J. Gong, 2021, Annals of Oncology.

A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma.

D. Davar, J. Kirkwood, H. Kluger, 2018 .

Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases.

Jeffrey W. Clark, F. Hodi, M. Sznol, 2010 .

Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity.

B. Neyns, M. Maio, S. O’Day, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab

P. Hegde, J. Sosman, F. Hodi, 2019, Clinical Cancer Research.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

K. Morrissey, F. Hodi, M. Ahn, 2019, Clinical Cancer Research.

Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.

J. Larkin, J. Kirkwood, H. Kluger, 2020 .

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy)

G. Madonna, P. Ascierto, L. Zitvogel, 2022, Journal of Translational Medicine.

The “Great Debate” at Immunotherapy Bridge 2021, December 1st–2nd, 2021

P. Ascierto, J. Sosman, B. Fox, 2022, Journal of Translational Medicine.

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

H. Scher, C. Higano, K. Chìn, 2013 .

Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study

G. Linette, B. Neyns, C. Lebbé, 2008 .

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

J. Wolchok, H. Zarour, N. Ibrahim, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

459PRisk of pneumonitis in patients with advanced NSCLC treated with pembrolizumab in KEYNOTE-001

M. Ahn, S. Ramalingam, M. Hellmann, 2015 .

A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.

V. Sondak, J. Sosman, J. Kirkwood, 2017 .

The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017

M. Ross, R. Sullivan, P. Ascierto, 2018, Journal of Translational Medicine.

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Axel Hoos, Jedd D. Wolchok, J. Wolchok, 2009, Clinical Cancer Research.

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

James R. Anderson, J. Wolchok, H. Zarour, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.

J. Wolchok, S. Chasalow, S. O’Day, 2013, Cancer immunity.

Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma

S. Chasalow, S. Gnjatic, S. Galbraith, 2012, Journal of immunotherapy.

Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody

H. Pehamberger, J. Wolchok, F. Hodi, 2008 .

Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma

O. Hamid, J. Weber, D. Minor, 2008 .

Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment

J. Wolchok, P. Queirolo, K. Harmankaya, 2008 .

Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma

F. Hodi, S. O’Day, E. Hersh, 2007 .

Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts

Infante, K. Sikorska, M. Sznol, 2020, Journal of Translational Medicine.

P. Ascierto, R. Dummer, J. Wolchok, 2017, The Lancet. Oncology.

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.

J. Wolchok, B. Neyns, K. Harmankaya, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

7005 ORAL Ipilimumab (MDX-010) in patients with stage III/IV melanoma: kinetics and duration of response

S. O’Day, E. Hersh, W. Urba, 2007 .

Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.

J. Wolchok, H. Zarour, A. Ribas, 2015 .

A. Hauschild, D. Schadendorf, R. Dummer, 2016, European journal of cancer.

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.

R. Sullivan, R. Dummer, J. Kirkwood, 2021, The New England journal of medicine.

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.

P. Ascierto, R. Dummer, J. Wolchok, 2019, European journal of cancer.

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2015, Journal of Translational Medicine.

Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.

J. Wolchok, A. Ribas, F. Hodi, 2014 .

United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.

V. Sondak, J. Sosman, J. Kirkwood, 2019, Journal of Clinical Oncology.

Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.

P. Ascierto, R. Dummer, J. Wolchok, 2019, Journal of Clinical Oncology.

The Great Debate at “Melanoma Bridge”, Naples, December 7th, 2019

P. Ascierto, H. Zarour, A. Testori, 2020, Journal of Translational Medicine.

4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

James R. Anderson, J. Larkin, A. Ribas, 2018 .

Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.

M. Atkins, F. Hodi, H. Tawbi, 2017 .

Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).

M. Atkins, F. Hodi, H. Tawbi, 2019, Journal of Clinical Oncology.

Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer.

P. LoRusso, T. Bekaii-Saab, E. Chan, 2015 .

Pharmacodynamic and efficacy analysis of the BRAF inhibitor dabrafenib (GSK436) in combination with the MEK inhibitor trametinib (GSK212) in patients with BRAFV600 mutant colorectal cancer (CRC).

C. Atreya, R. Kurzrock, D. Ryan, 2013 .

Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.

I. Puzanov, M. Milhem, H. Kaufman, 2015 .

9304 Identification of tumor biopsy markers as potential predictors of ipilimumab clinical activity in patients with advanced melanoma

S. Aamdal, S. Chasalow, H. Schmidt, 2009 .

Treatment patterns of melanoma by BRAF mutation status in the USA from 2011 to 2017: a retrospective cohort study

O. Hamid, L. Raskin, D. Cohan, 2019, Melanoma management.

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

M. Atkins, F. Hodi, H. Tawbi, 2021, Neuro-oncology.

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

N. Rizvi, P. Ott, A. El-Khoueiry, 2022, Journal for ImmunoTherapy of Cancer.

Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.

I. Puzanov, M. Milhem, H. Kaufman, 2014 .

Radiation and Melanoma: A Phoenix Rising

S. Shiao, O. Hamid, 2015 .

789 Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: pooled analysis of consecutive cohorts (C-144–01 study)

J. Kirkwood, P. Hari, H. Kluger, 2022, Regular and Young Investigator Award Abstracts.

Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001.

J. Wolchok, H. Zarour, A. Ribas, 2015 .

Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial

Douglas B. Johnson, E. Espinosa, A. Shoushtari, 2022, Nature Medicine.

Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma.

J. Larkin, A. Ribas, C. Blank, 2020 .

Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study.

M. Gross, J. Hainsworth, L. Hart, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

A. Ribas, F. Hodi, J. Schachter, 2018, British Journal of Cancer.

P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

J. Wolchok, H. Zarour, A. Ribas, 2015 .

LBA34PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED MELANOMA (MEL): RANDOMIZED COMPARISON OF TWO DOSING SCHEDULES

J. Wolchok, H. Zarour, A. Ribas, 2014 .

Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials.

J. Wolchok, B. Neyns, K. Harmankaya, 2013 .

Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results.

J. Wolchok, F. Hodi, M. Sznol, 2012 .

Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer

D. McGovern, R. Paquette, J. V. Van Eyk, 2021, Cancer Research.

Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

R. Fisher, A. Ribas, F. Hodi, 2019, Nature Medicine.

Optimal systemic therapy for high-risk resectable melanoma

A. Eggermont, O. Hamid, J. Luke, 2022, Nature Reviews Clinical Oncology.

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

M. Weichenthal, K. Kähler, P. Ascierto, 2022, Journal for ImmunoTherapy of Cancer.

Abstract CT079: Durable responses to avelumab (anti-PD-L1) in patients with Merkel cell carcinoma progressed after chemotherapy: 1-year efficacy update

S. D'Angelo, K. Lewis, C. Lebbé, 2017 .

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

A. Ribas, I. Puzanov, A. Daud, 2019, Clinical Cancer Research.

Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).

J. Wolchok, A. Ribas, F. Hodi, 2014 .

Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up

G. Linette, S. D'Angelo, K. Lewis, 2021, ESMO open.

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study.

Christopher J. Miller, D. Schadendorf, A. Gesierich, 2014 .

An immune-active tumor microenvironment favors clinical response to ipilimumab

Rui-Ru Ji, Nathan O. Siemers, Henrik Schmidt, 2012, Cancer Immunology, Immunotherapy.

Case report: Later onset of NRAS-mutant metastatic melanoma in a patient with a partially-excised giant congenital melanocytic nevus

S. Gandhi, O. Hamid, B. A. Costa, 2022, Frontiers in Medicine.

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

A. Hauschild, D. Schadendorf, P. Ascierto, 2017, European journal of cancer.

BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212).

R. Kurzrock, D. Ryan, A. Venook, 2012 .

A randomized, open‐label clinical trial of tasisulam sodium versus paclitaxel as second‐line treatment in patients with metastatic melanoma

A. Hauschild, A. Arance, C. Garbe, 2014, Cancer.

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Antoni Ribas, Caroline Robert, Anthony M Joshua, 2013, The New England journal of medicine.

Treatment patterns of malignant melanoma in the United States from 2011 to 2016: a retrospective cohort study

O. Hamid, L. Raskin, D. Cohan, 2020, Current medical research and opinion.

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

A. Hauschild, D. Schadendorf, A. Gesierich, 2017, BMC Cancer.

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

A. Ribas, C. Blank, A. Arance, 2017, The Lancet.

Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)

S. O’Day, W. Urba, O. Hamid, 2007, Cancer.

KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.

P. Ascierto, A. Ribas, M. Del Vecchio, 2021, European journal of cancer.

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

J. Larkin, A. Ribas, C. Blank, 2019, The Lancet. Oncology.

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

R. Sullivan, F. Hodi, H. Tawbi, 2019, Nature Medicine.

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

R. Fisher, A. Ribas, F. Hodi, 2019, Nature Medicine.

Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma

M. Sznol, A. Shoushtari, J. Infante, 2020, Clinical Cancer Research.

LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial

R. Carvajal, A. Dowlati, O. Hamid, 2021, Investigational New Drugs.

Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

K. Cornetta, A. Ishiyama, J. Heath, 2014, Clinical Cancer Research.

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

K. Lewis, C. Lebbé, M. Milella, 2018, Journal of Immunotherapy for Cancer.

Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

James R. Anderson, R. Dummer, J. Larkin, 2018 .

Efficacy/safety of epacadostat plus pembrolizumab in triple-negative breast cancer and ovarian cancer: Phase I/II ECHO-202 study.

David C. Smith, E. Schmidt, V. Borges, 2017 .

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.

D. Schadendorf, P. Ascierto, M. Smylie, 2017, The Lancet. Oncology.

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

G. Linette, K. Lewis, C. Lebbé, 2016, The Lancet. Oncology.

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

P. Ascierto, R. Dummer, J. Wolchok, 2015, The Lancet. Oncology.

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

A. Giobbie-Hurder, C. Antonescu, R. Sullivan, 2015, Clinical Cancer Research.

Selecting patients for KIT inhibition in melanoma.

C. Antonescu, R. Carvajal, O. Hamid, 2014, Methods in molecular biology.

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

D. Schadendorf, P. Ascierto, R. Dummer, 2017, European journal of cancer.

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

Dirk Schadendorf, Alessandro Testori, Axel Hauschild, 2014, The Lancet. Oncology.

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

M. Brown, R. Kurzrock, J. Infante, 2012, The Lancet.

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

J. Larkin, J. Kirkwood, H. Kluger, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma

A. Pavlick, S. O’Day, M. Albertini, 2012, Investigational New Drugs.

Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial

Parantu K. Shah, G. Linette, K. Lewis, 2020, Journal for immunotherapy of cancer.

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

J. Taube, C. Harview, R. Dummer, 2017, Cancer Immunology Research.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

Programmed death 1 immune checkpoint inhibitors.

R. Carvajal, O. Hamid, M. Trivedi, 2015, Clinical advances in hematology & oncology : H&O.

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

David C. Smith, E. Schmidt, A. Balmanoukian, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.

David C. Smith, E. Schmidt, O. Hamid, 2017 .

Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase I/II results from ECHO-202/KEYNOTE-037.

David C. Smith, E. Schmidt, A. Balmanoukian, 2017 .

The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020

V. Sondak, P. Ascierto, M. Atkins, 2021, Journal of translational medicine.

Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC).

H. Scher, C. Higano, I. Lowy, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved survival in women versus men with merkel cell carcinoma.

M. Luu, A. Ho, C. Barker, 2020, Journal of the American Academy of Dermatology.

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.

P. Hegde, T. Powles, J. Sosman, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

T. Curiel, M. Rebelatto, N. Segal, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).

Patrick Schöffski, Keith Steele, J. Nemunaitis, 2015 .

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

J. Wolchok, F. Hodi, M. Sznol, 2012, The Lancet. Oncology.

The great debate at “Immunotherapy Bridge 2018”, Naples, November 29th, 2018

G. Freeman, P. Ascierto, A. Mantovani, 2019, Journal of Immunotherapy for Cancer.

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

A. Hauschild, M. Ross, I. Puzanov, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors

R. Loberg, P. LoRusso, T. Bekaii-Saab, 2018, Clinical Cancer Research.

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

C. Atreya, R. Kurzrock, D. Ryan, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type

A. Ghazalpour, N. Xiao, D. V. Von Hoff, 2014, Cancer Epidemiology, Biomarkers & Prevention.

A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

J. Sosman, R. Herbst, F. Hodi, 2013 .

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.

P. Hwu, M. Sznol, P. Ott, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) in patients (pts) with advanced melanoma.

P. Hwu, M. Sznol, H. Kluger, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I/II study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III/IV melanoma

P. Hwu, M. Sznol, H. Kluger, 2008 .

Phase II Study of Nab-Paclitaxel and Bevacizumab as First-line Therapy for Patients with Unresectable Stage III and IV Melanoma

O. Hamid, R. Weber, P. Boasberg, 2015, American journal of clinical oncology.

Atypical clinical response patterns to ipilimumab.

O. Hamid, B. Ledezma, S. Binder, 2011, Clinical journal of oncology nursing.

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Henrik Schmidt, Johan Hansson, Scott D Chasalow, 2011, Journal of Translational Medicine.

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

A. Maraveyas, S. O’Day, O. Hamid, 2009, Clinical Cancer Research.

Letter Regarding Editorial by Samuel Zagarella.

P. Ascierto, A. Cochran, C. Blank, 2020, The American Journal of dermatopathology.

Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.

R. Plummer, V. Giranda, P. Friedlander, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

A. Hauschild, D. Schadendorf, A. Gesierich, 2017, BMC Cancer.

Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management

M. Postow, R. Carvajal, O. Hamid, 2012, Current Oncology Reports.

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

J. Wolchok, A. Ribas, F. Hodi, 2018, Clinical Cancer Research.

A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma

D. Schadendorf, A. Pavlick, K. Lewis, 2018, Investigational New Drugs.

Characteristics of pyrexia in BRAF V 600 E / K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I / II clinical trial

K. Flaherty, J. Sosman, J. Infante, 2015 .

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.

A. Ribas, I. Puzanov, A. Daud, 2014, The Lancet. Oncology.

Sunitinib Therapy for Melanoma Patients with KIT Mutations

S. O’Day, B. Bastian, M. Kashani-Sabet, 2012, Clinical Cancer Research.

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

K. Flaherty, J. Sosman, I. Puzanov, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

R. Dummer, J. Wolchok, A. Ribas, 2020, European journal of cancer.

Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study

M. Sznol, D. Hong, F. Fox, 2020, Clinical Cancer Research.

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma

R. Carvajal, O. Hamid, M. Faries, 2019, Cancers.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

V. Sondak, J. Taube, M. Ross, 2019, The Lancet. Oncology.

A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma

Douglas B. Johnson, P. Ott, L. Hart, 2019, Cancer.

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma

G. Gibney, O. Hamid, J. Weber, 2019, Journal of Immunotherapy for Cancer.

Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma

G. Linette, M. Schlichting, K. Lewis, 2019, Cancer Immunology, Immunotherapy.

Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.

G. Linette, K. Lewis, C. Lebbé, 2018 .

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial.

K. Flaherty, J. Sosman, J. Infante, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors.

P. Hwu, J. Wigginton, A. Gupta, 2012 .

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

A. Hauschild, K. Flaherty, P. Ascierto, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

J. Wolchok, H. Zarour, A. Ribas, 2016, JAMA.

The association between facility volume and overall survival in patients with Merkel cell carcinoma

M. Luu, A. Ho, Z. Zumsteg, 2020, Journal of surgical oncology.

Identifying patients at risk for recurrent or advanced BCC.

O. Hamid, G. Goldenberg, 2013, Journal of Drugs in Dermatology.

Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?

I. Codreanu, O. Hamid, F. Limonadi, 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

Jeffrey Weber, Keith T Flaherty, Zeynep Eroglu, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

K. Flaherty, J. Sosman, Douglas B. Johnson, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials.

H. Pehamberger, G. Linette, J. Wolchok, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases

P. Ascierto, J. Wolchok, I. Puzanov, 2013 .

A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States

G. Linette, J. Hainsworth, K. Flaherty, 2014, Cancer journal.

Immunotherapy Bridge 2021 and Melanoma Bridge 2021: meeting abstracts

R. Sullivan, R. Dummer, J. Kirkwood, 2022, Journal of Translational Medicine.

Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.

Melissa L. Johnson, K. Papadopoulos, Sang-We Kim, 2021 .

Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

A. Hauschild, D. Schadendorf, A. Gesierich, 2019, BMC Cancer.

Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

A. Hauschild, D. Schadendorf, A. Gesierich, 2019, BMC Cancer.

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Michael E. Egger, J. Kirkwood, P. Hari, 2022, Journal for ImmunoTherapy of Cancer.

Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy.

J. Kirkwood, H. Kluger, K. Lewis, 2021, Journal of Clinical Oncology.

1214OEpacadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037

E. Schmidt, A. Balmanoukian, A. Frankel, 2017 .

511 Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma

G. Gibney, O. Hamid, J. Weber, 2015 .

Eruptive squamous cell carcinomas associated with BRAF-inhibitor therapy in a patient with metastatic melanoma.

O. Hamid, N. Ezra, D. Behroozan, 2012, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.

J. Wolchok, H. Zarour, A. Ribas, 2018 .

Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2016 .

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

R. Govindan, F. Hirsch, M. Brown, 2014, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

D. Schadendorf, P. Ascierto, A. Ribas, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)

F. Marincola, G. Botti, P. Ascierto, 2019, Journal of Translational Medicine.

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

Donnell, T. Curiel, M. Rebelatto, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development and Validation of a Modified Pathologic Nodal Classification System for Cutaneous Melanoma.

M. Luu, A. Ho, Z. Zumsteg, 2021, JAMA surgery.

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

J. Wolchok, A. Ribas, F. Hodi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386)

J. Wolchok, A. Ribas, F. Hodi, 2018 .

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab

S. Chasalow, H. Schmidt, J. Jackson, 2012, Cancer Immunology, Immunotherapy.

A phase I study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients (pts) with advanced solid tumors.

H. Rugo, R. Carvajal, A. Dowlati, 2017 .

18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.

G. Linette, K. Lewis, C. Lebbé, 2018 .

Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab.

J. Wolchok, S. Chasalow, S. O’Day, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

A. Ribas, F. Hodi, J. Schachter, 2018, British Journal of Cancer.

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

V. Sondak, J. Sosman, J. Kirkwood, 2021, Journal for ImmunoTherapy of Cancer.

Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204.

J. Berlin, A. Daud, K. Lewis, 2017 .

Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy

R. Dummer, O. Hamid, M. Levesque, 2017, British Journal of Cancer.

First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results.

D. Nuyten, A. El-Khoueiry, O. Hamid, 2016 .

Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers

David C. Smith, D. Kaufman, A. Balmanoukian, 2015, Journal of Immunotherapy for Cancer.

A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab (MSB0010718C) in patients with metastatic Merkel cell carcinoma.

P. Nghiem, H. Kaufman, O. Hamid, 2015 .

Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies.

L. Chow, O. Hamid, J. Gray, 2015 .

Systemic treatment of metastatic melanoma: New approaches

S. O’Day, O. Hamid, P. Boasberg, 2011, Journal of surgical oncology.

Ipilimumab in Treatment-naive and Previously Treated Patients with Metastatic Melanoma: Retrospective Analysis of Efficacy and Safety Data from a Phase II Trial

O. Hamid, J. Weber, D. Minor, 2012, Journal of immunotherapy.

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.

J. Larkin, J. Kirkwood, H. Kluger, 2019, Journal of Clinical Oncology.

Ipilimumab for metastatic melanoma.

R. Carvajal, O. Hamid, J. Ozao-Choy, 2012, Drugs of today.

Quantitative Metastatic Lymph Node Burden and Survival in Merkel Cell Carcinoma

M. Luu, A. Ho, Z. Zumsteg, 2019, International Journal of Radiation Oncology*Biology*Physics.

Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E/K-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.

P. Ascierto, A. Ribas, H. Schmidt, 2022, Journal of Clinical Oncology.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, David C. Smith, A. Hauschild, 2016, Journal of Translational Medicine.

Pharmacodynamic effect of IMCgp100 (TCR–CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma.

M. Sznol, A. Shoushtari, J. Infante, 2019, Journal of Clinical Oncology.

1216OKEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma

R. Fisher, A. Ribas, F. Hodi, 2017 .

Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.

R. Sullivan, F. Hodi, P. Hwu, 2017 .

Ipilimumab, nivolumab and tocilizumab as first-line therapy for advanced melanoma.

F. Hodi, O. Hamid, J. Weber, 2021 .

Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM).

K. Flaherty, Douglas B. Johnson, S. Patel, 2017 .

Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

Jedd D. Wolchok, Antoni Ribas, Richard F. Kefford, 2016 .

Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer.

T. Curiel, M. Rebelatto, N. Segal, 2016 .

mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

A. Hauschild, D. Schadendorf, R. Dummer, 2014 .

Effect of prior treatment status on the efficacy and safety of ipilimumab monotherapy in treatment-naive and previously treated patients with advanced melanoma

O. Hamid, J. Weber, D. Minor, 2008 .

Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma

M. Ross, I. Puzanov, M. Milhem, 2016 .

Prophylatic cranial irradiation (PCI) in patients (Pts) with stage IV metastatic melanoma (MM) receiving concurrent biochemotherapy (cBCT) and maintenance biotherapy (MBT)

S. O’Day, O. Hamid, J. Weber, 2008 .

Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis

S. Freedland, S. Pal, O. Hamid, 2019, JAMA oncology.

Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma

M. Sznol, B. Jakobsen, A. Shoushtari, 2016 .

Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis.

J. Hainsworth, O. Hamid, L. Fayad, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.

R. Dummer, Toshio Shimizu, F. Meric-Bernstam, 2019, Journal of Clinical Oncology.

Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037

David C. Smith, D. Kaufman, A. Balmanoukian, 2016 .

Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma.

K. Flaherty, J. Sosman, I. Puzanov, 2012 .

P860 Results from a combination of OX40 (PF-04518600) and 4–1BB (utomilumab) agonistic antibodies in melanoma and non-small cell lung cancer in a phase 1 dose expansion cohort

N. Rizvi, S. Hu-Lieskovan, J. Spano, 2020, Journal of Immunotherapy for Cancer.

A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers

A. El-Khoueiry, S. Hu-Lieskovan, S. Salek-Ardakani, 2021, Clinical Cancer Research.

Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma

R. Yeh, P. LoRusso, J. Infante, 2019, Investigational New Drugs.

Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab.

S. Chasalow, Z. Tsuchihashi, S. Galbraith, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1757O Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients

H. Sethi, E. Espinosa, A. Shoushtari, 2021, Annals of Oncology.

Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator’s choice (IC) in first-line metastatic uveal melanoma.

R. Sullivan, R. Dummer, J. Kirkwood, 2021 .

64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM)

Takuro Sato, Douglas B. Johnson, E. Espinosa, 2020 .

Combination of the STING Agonist MIW815 and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-label, Multicenter, Phase Ib Study.

R. Dummer, F. Meric-Bernstam, G. Long, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)

J. Wolchok, H. Zarour, A. Ribas, 2014, Journal of Immunotherapy for Cancer.

A first-in-human (FIH) study of PF-04518600 (PF-8600) OX40 agonist in adult patients (pts) with select advanced malignancies

A. El-Khoueiry, O. Hamid, T. Joh, 2016 .

First-in-human study of AMG 337, a highly selective oral inhibitor of MET, in adult patients (pts) with advanced solid tumors.

R. Loberg, P. LoRusso, E. Kwak, 2014 .

Endocrine autoantibodies determine immune checkpoint inhibitor-induced endocrinopathy: a prospective study.

S. Melmed, L. Piro, O. Hamid, 2022, The Journal of clinical endocrinology and metabolism.

9312 Antitumor responses to ipilimumab in advanced melanoma are not affected by systemic corticosteroids used to manage immune-related adverse events (irAEs)

J. Wolchok, B. Neyns, J. Grob, 2009 .

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Correlation between metastatic site and response to anti-Programmed Death-1 (PD-1) agents in melanoma.

R. Dummer, A. Daud, O. Hamid, 2016 .

Gemcitabine, Oxaliplatin, and Paclitaxel (GOT) on a 2-Weekly Schedule in Patients (PTS) with Refractory Germ Cell Carcinoma: A Phase II Study Conducted at the University of Southern California

S. Groshen, J. Pinski, T. Dorff, 2012 .

Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.

A. Ravaud, K. Kelly, T. Stinchcombe, 2016 .

Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future

O. Hamid, P. Corrie, A. Betof Warner, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

1040O Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma

R. Sullivan, F. Hodi, O. Hamid, 2021, Annals of Oncology.

Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial.

G. Linette, K. Lewis, C. Lebbé, 2016 .

Phase II trial of nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable melanoma.

S. O’Day, O. Hamid, R. Weber, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract A20: MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity.

J. Lunceford, M. Dolled-Filhart, K. Emancipator, 2014 .

Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma.

P. Hwu, M. Sznol, H. Kluger, 2010 .

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

R. Plummer, E. D. de Vries, P. Ott, 2021, Journal for ImmunoTherapy of Cancer.

Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data.

S. Freedland, S. Pal, O. Hamid, 2020, Japanese journal of clinical oncology.

Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO-202/KEYNOTE-037.

David C. Smith, E. Schmidt, V. Borges, 2017 .

Abstract CT002: Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma

R. Sullivan, R. Dummer, J. Kirkwood, 2021, Clinical Trials.

Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIB/IV NSCLC.

M. Ahn, N. Segal, A. Gupta, 2017 .

Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study.

M. Gross, J. Hainsworth, L. Hart, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract LB-288: A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

F. Hodi, G. Fine, O. Hamid, 2013 .

The Great Debate at “Melanoma Bridge”, Naples, December 7th, 2019

P. Ascierto, H. Zarour, A. Testori, 2020, Journal of Translational Medicine.

Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.

C. Atreya, R. Kurzrock, D. Ryan, 2014 .

Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.

J. Larkin, A. Ribas, C. Blank, 2017 .

Pharmacokinetics (PK) of CR011-vcMMAE, an antibody-drug conjugate (ADC), in a phase (Ph) I study of patients (pts) with advanced melanoma.

P. Hwu, M. Sznol, H. Kluger, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy in metastatic melanoma

O. Hamid, M. Faries, Devin C. Flaherty, 2015, Journal of surgical oncology.

Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

J. Wolchok, J. Larkin, C. Robert, 2020, Clinical Cancer Research.

melanoma and other skin tumoursIpilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial

P. Ascierto, R. Dummer, J. Wolchok, 2016 .

Analysis of serum biomarkers and tumor genetic alterations from a phase II study of lenvatinib in patients with advanced BRAF wild-type melanoma.

A. Hauschild, K. Flaherty, C. Andresen, 2013 .

Immunotherapy Bridge 2018 and Melanoma Bridge 2018: meeting abstracts

Hosein, Inge, P. Ascierto, 2019, Journal of Translational Medicine.

The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017

M. Ross, R. Sullivan, P. Ascierto, 2018, Journal of Translational Medicine.

A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma.

A. Hauschild, J. Hainsworth, K. Flaherty, 2013 .

Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T).

K. Flaherty, J. Sosman, M. Sznol, 2013 .

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2015, Journal of Translational Medicine.

Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)

F. Marincola, G. Botti, P. Ascierto, 2019, Journal of Translational Medicine.

Extended follow-up results of a phase 1B study (BRIM7) of cobimetinib (C) and vemurafenib (V) in BRAF-mutant melanoma.

A. Ribas, I. Puzanov, A. Daud, 2016 .

Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma.

A. Ribas, I. Puzanov, A. Pavlick, 2015 .

Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies

O. Hamid, J. Gray, L. Chow, 2016 .

CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072.

P. LoRusso, A. El-Khoueiry, A. Naing, 2019, Journal of Clinical Oncology.

Nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable stage III and IV melanoma.

O. Hamid, R. Weber, P. Boasberg, 2009, Journal of Clinical Oncology.

Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma

James R. Anderson, J. Larkin, A. Ribas, 2019, Clinical Trials.

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study

P. Ascierto, J. Kirkwood, A. Shoushtari, 2023, Journal for ImmunoTherapy of Cancer.

Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

R. Fisher, A. Ribas, F. Hodi, 2019, Nature Network Boston.

Melanoma and other skin tumors

Y. S. Kim, Su Jin Lee, J. Utikal, 2012 .

Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma.

J. Wolchok, H. Zarour, A. Ribas, 2013 .

A phase II study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.

Douglas B. Johnson, P. Ott, L. Hart, 2017 .

Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma

J. Larkin, A. Ribas, C. Blank, 2015 .

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

A. Hauschild, C. Garbe, P. Friedlander, 2023, Journal for ImmunoTherapy of Cancer.

Efficacy of ipilimumab 10 mg/kg in advanced melanoma patients (pts) with good and poor prognostic factors.

G. Linette, J. Wolchok, V. Chiarion-Sileni, 2009, Journal of Clinical Oncology.

The relationship of pharmacodynamics (PD) and pharmacokinetics (PK) to clinical outcomes in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600).

A. El-Khoueiry, S. Hu-Lieskovan, O. Hamid, 2017 .

Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.

I. Lowy, K. Papadopoulos, J. Crown, 2023, Journal of Clinical Oncology.

Assessment of association between BRAF mutation status in melanoma tumors and response to ipilimumab.

S. Chasalow, H. Schmidt, Y. Bao, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763).

D. Schadendorf, P. Ascierto, A. Ribas, 2014 .

A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy.

A. Oza, H. Hirte, E. Kaldjian, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

19O Preliminary safety, antitumor activity and pharmacodynamics results of HIT-IT MEDI1191 (mRNA IL-12) in patients with advanced solid tumours and superficial lesions

T. Marron, B. Carneiro, J. Eyles, 2021 .

Co-expression patterns of immune checkpoint molecules in relation to PD-L1 expression.

Charles J. Vaske, S. Benz, J. Z. Sanborn, 2018 .

809OIMMUNE CORRELATES AND LONG TERM FOLLOW UP OF A PHASE IA STUDY OF MPDL3280A, AN ENGINEERED PD-L1 ANTIBODY, IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC).

T. Powles, J. Sosman, M. Sznol, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Complete and Sustained Remission of Metastatic Cutaneous Squamous Cell Carcinoma in a Liver Transplant Patient Treated With Talimogene Laherparepvec.

Z. Zumsteg, N. Gharavi, O. Hamid, 2020, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

Ipilimumab (IPI) Expanded Access Program (EAP) for Patients (PTS) with Stage III/IV Melanoma: Safety Data by Subgroups

J. Wolchok, F. Hodi, D. Lawrence, 2012 .

140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)

J. Lunceford, J. Wolchok, H. Zarour, 2014 .

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

J. Wolchok, A. Ribas, F. Hodi, 2018, Clinical Cancer Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 18-month update of the pivotal ERIVANCE BCC study.

D. Schadendorf, A. Gesierich, C. Garbe, 2013 .

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

C. Atreya, R. Kurzrock, D. Ryan, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1093PDVEMURAFENIB AND COBIMETINIB POTENTLY INHIBIT PS6 SIGNALING IN BRAFV600 MUTATION-POSITIVE LOCALLY ADVANCED OR METASTATIC MELANOMA FROM BRIM7 STUDY.

A. Ribas, R. Gonzalez, I. Puzanov, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab versus Ipilimumab in Advanced Melanoma.

J. Larkin, A. Ribas, C. Blank, 2015, The New England journal of medicine.

Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type

A. Ghazalpour, N. Xiao, D. V. Von Hoff, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

J. Taube, C. Harview, R. Dummer, 2017, Cancer Immunology Research.

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

J. Wolchok, A. Ribas, F. Hodi, 2018, Clinical Cancer Research.

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.

A. Ribas, I. Puzanov, A. Daud, 2014, The Lancet. Oncology.

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

R. Fisher, A. Ribas, F. Hodi, 2019, Nature Medicine.

A phase Ib study of CUDC-101, a multitargeted inhibitor of EGFR, HER2, and HDAC, in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer.

J. Nemunaitis, J. Bauman, G. Dy, 2012 .

P. Ascierto, R. Dummer, J. Wolchok, 2017, The Lancet. Oncology.

Abstract CT233: A first-in-human phase I study of the safety and pharmacokinetic (PK) activity of DEDN6526A, an anti-endothelin B receptor (ETBR) antibody-drug conjugate (ADC), in patients with metastatic or unresectable melanoma

J. Infante, C. McNeil, O. Hamid, 2014 .

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

K. Flaherty, J. Sosman, I. Puzanov, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

J. Wolchok, A. Ribas, F. Hodi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Distribution of PD-L1 expression in diverse cancer types: Experience with over 10,000 cases.

M. Atkins, Z. Gatalica, O. Hamid, 2016 .

Immunotherapy Bridge 2018 and Melanoma Bridge 2018: meeting abstracts

Hosein, Inge, P. Ascierto, 2019, Journal of Translational Medicine.

Population pharmacokinetic (popPK) model of pembrolizumab (pembro; MK-3475) in patients (pts) treated in KEYNOTE-001 and KEYNOTE-002.

A. Ribas, F. Hodi, C. Blank, 2015 .

Sunitinib Therapy for Melanoma Patients with KIT Mutations

B. Bastian, M. Kashani-Sabet, O. Hamid, 2012, Clinical Cancer Research.

A Pooled analysis of 655 patients with advanced melanoma enrolled in keynote-001 : long-term efficacy of pembrolizumab (mk-3475)

J. Wolchok, H. Zarour, A. Ribas, 2015 .

ipilimumab Versus Placebo After Complete Resection Of Stage Iii Melanoma: Efficacy And Safety Results From The Eortc 18071 Phase Iii Trial : 374

P. Ascierto, R. Dummer, J. Wolchok, 2014 .